BrightGene Bio-Medical Technology announced that the company has decided to terminate its previously planned issuance of H shares and listing on the Main Board of the Hong Kong Stock Exchange, and will no longer proceed with the supplementary filing. The company convened a board meeting on September 30, 2026, to review and approve the relevant proposal, and this termination does not require submission to the shareholders' meeting for approval. The company stated that the termination is a prudent decision made after comprehensively weighing multiple factors and considering the actual situation, and will not have a material adverse impact on its production, operations, or sustainable development.
BrightGene Bio Medical Technology CBrightGene terminates its planned H-share issuance and Hong Kong Main Board listing, scrapping a financing/listing event.
